Clinical trial SHRINK
CELYAD SHRINK : An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer
Cancers | |
---|---|
Organ | Colon |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1 |
Academic trial | Non |
Sponsor | Celyad |
EudraCT Identifier | 2017-000616-41 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03310008 |
Inclusion criteria | Biopsy mandatory neoadjuvant |
Last update |